The mos protooncogene has opposing dfects on cell cycle pgression. It is required for reitatlon of meiotic maturation and for meiotic progression through metaphase II, yet it is an active component of cytostatic factor. mos is a potent oncogene in fibroblasts, but high levels of expion are lethal. 
dosage in mitotic cells. We have directly tested whether expression of the Mos protein can block mitosis in mammalian cells by mnicroecting a fusion protein between Esckerichia coli maltose-binding protein and Xenopus c-Mos Into PtK1 epithelial cells and analyzing the cells by video time-lapse and immunofluorescence microscopy. Time-course analyses showed that Mos blocked mitosis by preventing progression to a normal metaphase. Chromosomes frequently falled to attain a bipolar orientation and were found near one pole. InJection of a kinase-deficlent mutant Mos had no effect on mitosis, indicating that the blockage of mitotic progression required Mos kinase activity. Antitubulin immunostaining of cells blocked by Mos showed that microtubules were present but that spindle morphology was abnormal. Immunotalning for the Mos fusion protein showed that both wild-type and kinase mutant proteins-localized at the kinetochores. Our results suggest that mitotic blockage by Mos may result from an action of the Mos kinase on the kinetochores, thus increasing chromosome instability and preventing normal congression.
Early transformation studies of fibroblasts with v-mos showed that a majority of cells acutely infected with Moloney murine sarcoma virus rounded up, detached from the monolayer, and failed to proliferate (1) (2) (3) . This cytotoxic effect of the v-mos product has been proposed to be related to the cytostatic factor (CSF) activity of Mos in unfertilized eggs (4) . CSF is an activity believed to be responsible for the natural arrest of oocytes in metaphase II of meiosis and was originally discovered as an activity in unfertilized eggs that inhibited mitosis in early cleavage embryos (5) .
The identified cellular activities of Mos depend upon its function as a serine/threonine protein kinase. The ability of
Mos to reinitiate oocyte maturation (4, 6, 7) , provide CSF activity (8) , and transform fibroblasts (3, 9) is abolished in a protein kinase-deficient mutant of Mos with an anino acid substitution (Lys9 -Arg) in the canonical ATP binding site (7, 10) . Several candidate substrates of Mos have been suggested from in vitro experiments, including cyclin B2 (11) and tubulin (12) . Most recently, Mos has been shown to stimulate mitogen-activated protein kinase (MAP kinase), entering the MAP kinase phosphorylation cascade apparently by direct activation of MAP kinase kinase (13) .
Long before the mos protooncogene product was found to be a regulator of meiosis, the ability of v-mos and its cellular homolog, c-mos, to transform fibroblast cells (14) . Cells microinjected into the cytoplasm with MBP-Mosxe progressed through nuclear envelope breakdown normally but generally failed to form a metaphase plate ( Fig. 1 Left). The PtK1 cells became atypically rounded and remained blocked in a mitotic state with condensed chromosomes. All cells were monitored for at least 3 hr and some were monitored for up to 6 hr.
Cells were scored for mitotic inhibition according to the severity of the phenotype. A strong (terminal) phenotype was defined as failure of all chromosomes to form a stable metaphase plate, extreme cell rounding, and failure of the cells to divide. A weak (unstable) phenotype was defined as failure of some chromosomes to arrive at the metaphase plate, some rounding, abnormal anaphase (failure of sister chromosome segregation or nondisjunction), followed by either failure of cleavage or uneven cleavage that altered ploidy. By these criteria, microinjection of Mos at a needle concentration of 0.5 mg/ml inhibited mitosis and produced a terminal phenotype in 70%6 of the cells ( The specificity of action of Mos on mitotic cells was evaluated in several ways. First, the possibility of nonspecific injury to cells due to microinjection was assessed by injection of buffer alone. Cells were injected at various stages from mid-prophase to metaphase. All 34 cells injected divided normally (Fig. 2) , indicating no detectable effect of microinjection per se. Second, the action of Mos was dependent on concentration, with a lower concentration giving a lower proportion of the strong phenotype. When cells were injected with Mos at 0.25-mg/ml needle concentration, although mitotic blockage was still produced, a higher proportion of cells reached metaphase, and many cells displayed the weak phenotype (data not shown). Analysis of the time-lapse video records indicated that chromosomes frequently failed to display normal mitotic behavior. Either they failed to congress to the metaphase plate or they congressed and then subsequently became irregularly arranged. Resulting anaphases were abnormal in that sister chromosomes failed to segregate.
Although some rounding is normal for mitosis, Mosinjected mitotic cells became extremely rounded. To evaluate whether this effect was a nonspecific cytotoxic reaction on the PtK1 cells, interphase cells were also microinjected and observed for 3 hr. Microinjected interphase cells remained well spread and normal in appearance (data not shown). Therefore, the rounding effect was specific to mitotic cells, and we conclude that Mos is not generally cytotoxic to PtK1 epithelial cells.
Next, we determined whether the cellular effect of Mos was dependent on its kinase activity. The kinase-deficient mutant MBP-Mosxekm does not induce oocyte maturation or (Fig. 1 Right; Fig. 2 (Fig. 4 A-C (Fig. 4 D-G A line drawn through the sister kinetochores will be approximately parallel to the spindle axis. As is evident in Fig. 4B , several of the chromosomes fail this test, the line connecting their kinetochore dots pointing away from the spindle axis. Thus, at low Mos concentrations, although a bipolar spindle was formed, significant levels of malorientation were seen. Terminally arrested cells (high Mos concentration) failed to form a metaphase plate (see Fig. 1 ), which is an indicator of extreme malorientation in which most or all of the chromosomes failed to attach stably to both poles.
Injection of cells earlier in prophase allowed us to evaluate Mos distribution before nuclear envelope breakdown. Much of the Mos remained cytoplasmic, but some entered the nucleus and showed the paired dot staining characteristic of kinetochores. Cells injected with kinase-deficient Mos also showed nuclear entry and paired dot staining which we interpret to be kinetochores (Fig. 4 H and I) . The kinetochore localization of the mutant Mos indicates that binding to the kinetochores does not require kinase activity. Since injection of the mutant Mos failed to block mitotic progression, the results suggest that kinetochore binding in the absence of kinase activity is not sufficient to inhibit mitosis. To determine whether the MBP portion of the fusion protein contributed to the kinetochore localization of MBP-Mos, MBP The nonkinetochore microtubules ofthe mitotic spindle are highly dynamic whereas the kinetochore microtubules are more stable, presumably by virtue oftheir binding interaction Ceff Biblogy: Wang et al.
with the kinetochore (17) (18) (19) (20) . Stable, bipolar attachment of chromosomes to poles is required for normal chromosome congression (21) . The range of phenotypes and mitotic blockage produced by Mos can be readily accounted for in terms of a weakened attachment of kinetochores to spindle microtubules.
One important feature of prometaphase is that upon attachment to the spindle, the chromosomes undergo conspicuous oscillatory movements toward and away from the pole. The chromosome movements may be controlled by phosphorylation of kinetochore proteins, including motor molecules (22) . Both dynein and kinesin-like proteins have been localized at kinetochores (23) (24) (25) (26) . The localization of Mos at the kinetochore suggests that the Mos kinase could alter the normal phosphorylation pattern of the kinetochore proteins. A phosphorylated epitope in mammalian tissue culture cells has been found to be differentially expressed at the kinetochores of chromosomes in mitotic cells (27) . During prophase, label appeared at the kinetochores, and in early prometaphase, all the kinetochores were brightly labeled by the antibody. With progression through prometaphase, heterogeneity of labeling among the kinetochores became apparent. Chromosomes that were very near the poles were strongly labeled on both kinetochores. Those that were at the metaphase plate tended to be weakly labeled on one or both kinetochores. Chromosomes situated between the pole and the metaphase plate often exhibited asymmetric labeling of their two kinetochores, with greater labeling on the kinetochore toward the metaphase plate. Kinetochores in metaphase and anaphase cells exhibited no labeling with the antibody. Phosphorylation of the epitope may identify a regulatory event that controls chromosome movement to the metaphase plate. Dephosphorylation of the kinetochore epitope is correlated with acquisition of an attachment to a pole and subsequent movement to that pole. The introduction of Mos kinase into mitotic cells may phosphorylate some component(s) normally dephosphorylated in prometaphase which, in turn, could interfere with chromosome attachment and therefore mitotic progression.
Rattner et al. (28) showed that a portion of cellular p34cdc2 was localized to several distinct domains within the mitotic apparatus, including the kinetochore, spindle pole, and kinetochore microtubules. The detection of Cdc2 at specific sites within the mitotic apparatus may reflect the distribution of its substrate(s). Since both Cdc2 and Mos are localized at kinetochores and spindle poles and since Mos coimmunoprecipitates with p34cdc2 (29) , it is possible that the effect of Mos on the kinetochore may be mediated through an interaction or competition with cdc2. MAP kinase has been localized at spindle poles in mouse oocytes (30) , and Posada et al. (13) found that Mos activated MAP kinase kinase. Therefore, the effect of Mos on mitosis may be mediated through MAP kinase activity, as has been suggested in meiosis (31) . It remains an open question whether the Mos fusion protein is targeted to the same substrate(s) in mitosis as CSF/Mos is in meiosis II.
According to Yew et al. (32) , the level of Mos protein expression in c-mosxe-transformed mouse cells is =0.2% of the total protein. We estimate the concentration of Mos fusion protein required to produce the strong phenotype in our experiments to be about 2-fold higher than Mos protein levels in transformed cells. This result is consistent with the quantitation by Yew et al. (32) , because 2-fold dilution of the Mos fusion protein injected into cells reduced the effect, producing primarily the weak phenotype, and 3-fold diluted Mos did not cause any abnormal mitotic phenotype.
If Mos is superimposing a meiotic process on the mitotic program of somatic cells, it is not surprising that significant consequences for chromosome segregation will result. This, in turn, will result in genetic instability, which is considered to be the major component leading to tumor progression. Our studies demonstrate that the Mos oncogene product can negatively influence chromosome stability and mitotic progression. The conservation of the chromosome segregation mechanism suggests that the molecular identification of the Mos target(s) will prove worthwhile.
